{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T15:28:34Z","timestamp":1771342114987,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s12185-025-04084-z","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:11:35Z","timestamp":1760544695000},"page":"208-214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of polatuzumab vedotin versus conventional chemotherapy in relapsed or refractory diffuse large B-cell lymphoma"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3749-6025","authenticated-orcid":false,"given":"Tatsuzo","family":"Mishina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chika","family":"Manako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeaki","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Tsujimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoya","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"4084_CR1","doi-asserted-by":"crossref","unstructured":"Ohmachi K. JSH practical guidelines for hematological malignancies, 2023: II. lymphoma-overview. Int J Hematol. 2025:1\u201310.","DOI":"10.1007\/s12185-025-03920-6"},{"key":"4084_CR2","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"4084_CR3","doi-asserted-by":"crossref","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid Neoplasms. Leukemia. 2022;36:1720\u201348.","DOI":"10.1038\/s41375-022-01620-2"},{"key":"4084_CR4","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37:551-568.e14.","journal-title":"Cancer Cell"},{"key":"4084_CR5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679\u201390.","journal-title":"Nat Med"},{"key":"4084_CR6","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood.2019003535","volume":"135","author":"SE Lacy","year":"2020","unstructured":"Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a haematological malignancy research network report. Blood. 2020;135:1759\u201371.","journal-title":"Blood"},{"key":"4084_CR7","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/bjh.17765","volume":"195","author":"T Mishina","year":"2021","unstructured":"Mishina T, Oshima-Hasegawa N, Tsukamoto S, Fukuyo M, Kageyama H, Muto T, et al. Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort. Br J Haematol. 2021;195:731\u201342.","journal-title":"Br J Haematol"},{"key":"4084_CR8","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.ccell.2023.09.004","volume":"41","author":"M-C Zhang","year":"2023","unstructured":"Zhang M-C, Tian S, Fu D, Wang L, Cheng S, Yi H-M, et al. Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: the randomized GUIDANCE-01 trial. Cancer Cell. 2023;41:1705-1716.e5.","journal-title":"Cancer Cell"},{"key":"4084_CR9","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international scholar-1 study. Blood. 2017;130:1800\u20138.","journal-title":"Blood"},{"key":"4084_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41408-023-00970-z","volume":"14","author":"ERA Pennings","year":"2024","unstructured":"Pennings ERA, Durmaz M, Visser O, Posthuma EFM, Issa DE, Chamuleau MED, et al. Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands. Blood Cancer J. 2024;14:3.","journal-title":"Blood Cancer J"},{"key":"4084_CR11","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184\u201390.","journal-title":"J Clin Oncol"},{"key":"4084_CR12","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399:2294\u2013308.","journal-title":"Lancet"},{"key":"4084_CR13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales M-A, Ghobadi A, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023;389:148\u201357.","journal-title":"N Engl J Med"},{"key":"4084_CR14","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387:2220\u201331.","journal-title":"N Engl J Med"},{"key":"4084_CR15","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol. 2023;41:2238\u201347.","journal-title":"J Clin Oncol"},{"key":"4084_CR16","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1111\/cas.14937","volume":"112","author":"Y Terui","year":"2021","unstructured":"Terui Y, Rai S, Izutsu K, Yamaguchi M, Takizawa J, Kuroda J, et al. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed\/refractory diffuse large B-cell lymphoma. Cancer Sci. 2021;112:2845\u201354.","journal-title":"Cancer Sci"},{"key":"4084_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38:155\u201365.","journal-title":"J Clin Oncol"},{"key":"4084_CR18","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"4084_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/bjh.18197","volume":"198","author":"S Harrysson","year":"2022","unstructured":"Harrysson S, Eloranta S, Ekberg S, Enblad G, El-Galaly TC, Sander B, et al. Outcomes of relapsed\/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-a population-based study of 736 patients. Br J Haematol. 2022;198:267\u201377.","journal-title":"Br J Haematol"},{"key":"4084_CR20","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.1182\/bloodadvances.2022007609","volume":"6","author":"V Camus","year":"2022","unstructured":"Camus V, Belot A, Oberic L, Sibon D, Ghesqui\u00e8res H, Thieblemont C, et al. Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial. Blood Adv. 2022;6:6169\u201379.","journal-title":"Blood Adv"},{"key":"4084_CR21","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/jha2.970","volume":"5","author":"CP Fox","year":"2024","unstructured":"Fox CP, Townsend W, Gribben JG, Menne T, Kalakonda N, Williams P, et al. Real-world outcomes of patients with relapsed\/refractory large B-cell lymphoma receiving second-line therapy in England. EJHaem. 2024;5:992\u20137.","journal-title":"EJHaem"},{"key":"4084_CR22","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","volume":"23","author":"A Sehgal","year":"2022","unstructured":"Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022;23:1066\u201377.","journal-title":"Lancet Oncol"},{"key":"4084_CR23","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s00277-023-05273-8","volume":"102","author":"T Rattanathammethee","year":"2023","unstructured":"Rattanathammethee T, Norasetthada L, Bunworasate U, Wudhikarn K, Julamanee J, Noiperm P, et al. Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG). Ann Hematol. 2023;102:1887\u201395.","journal-title":"Ann Hematol"},{"key":"4084_CR24","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1182\/bloodadvances.2021005953","volume":"6","author":"M Northend","year":"2022","unstructured":"Northend M, Wilson W, Osborne W, Fox CP, Davies AJ, El-Sharkawi D, et al. Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed\/refractory DLBCL. Blood Adv. 2022;6:2920\u20136.","journal-title":"Blood Adv"},{"key":"4084_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/ejh.13784","volume":"109","author":"P Vodicka","year":"2022","unstructured":"Vodicka P, Benesova K, Janikova A, Prochazka V, Belada D, Mocikova H, et al. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed\/refractory diffuse large B-cell lymphoma in the real world. Eur J Haematol. 2022;109:162\u20135.","journal-title":"Eur J Haematol"},{"key":"4084_CR26","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1182\/bloodadvances.2020004155","volume":"5","author":"N Liebers","year":"2021","unstructured":"Liebers N, Duell J, Fitzgerald D, Kerkhoff A, Noerenberg D, Kaebisch E, et al. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv. 2021;5:2707\u201316.","journal-title":"Blood Adv"},{"key":"4084_CR27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/10428194.2020.1824069","volume":"62","author":"Y Segman","year":"2021","unstructured":"Segman Y, Ribakovsky E, Avigdor A, Goldhecht Y, Vainstein V, Goldschmidt N, et al. Outcome of relapsed\/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience. Leuk Lymphoma. 2021;62:118\u201324.","journal-title":"Leuk Lymphoma"},{"key":"4084_CR28","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.clml.2020.12.013","volume":"21","author":"SD Smith","year":"2021","unstructured":"Smith SD, Lopedote P, Samara Y, Mei M, Herrera AF, Winter AM, et al. Polatuzumab vedotin for relapsed\/refractory aggressive B-cell lymphoma: a multicenter post-marketing analysis. Clin Lymphoma Myeloma Leuk. 2021;21:170\u20135.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4084_CR29","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/hon.2842","volume":"39","author":"M Dimou","year":"2021","unstructured":"Dimou M, Papageorgiou SG, Stavroyianni N, Katodritou E, Tsirogianni M, Kalpadakis C, et al. Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. Hematol Oncol. 2021;39:336\u201348.","journal-title":"Hematol Oncol"},{"key":"4084_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2483390","author":"T Fujino","year":"2025","unstructured":"Fujino T, Okamoto H, Nishiyama D, Hayata H, Sasaki N, Kobayashi T, et al. Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study. Leuk Lymphoma. 2025;66:1425-1436.","journal-title":"Leuk Lymphoma"},{"key":"4084_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1200\/JCO.23.01097","volume":"42","author":"G Iacoboni","year":"2024","unstructured":"Iacoboni G, Navarro V, Mart\u00edn-L\u00f3pez A\u00c1, Rejeski K, Kwon M, Jalowiec KA, et al. Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy. J Clin Oncol. 2024;42:205\u201317.","journal-title":"J Clin Oncol"},{"key":"4084_CR32","doi-asserted-by":"publisher","first-page":"1322594","DOI":"10.3389\/fimmu.2023.1322594","volume":"14","author":"A Vanni","year":"2023","unstructured":"Vanni A, Salvati L, Mazzoni A, Lamacchia G, Capone M, Francalanci S, et al. Bendamustine impairs humoral but not cellular immunity to SARS-CoV-2 vaccination in rituximab-treated B-cell lymphoma-affected patients. Front Immunol. 2023;14:1322594.","journal-title":"Front Immunol"},{"key":"4084_CR33","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s00277-023-05204-7","volume":"102","author":"T Ishio","year":"2023","unstructured":"Ishio T, Tsukamoto S, Yokoyama E, Izumiyama K, Saito M, Muraki H, et al. Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma. Ann Hematol. 2023;102:1421\u201331.","journal-title":"Ann Hematol"},{"key":"4084_CR34","doi-asserted-by":"publisher","first-page":"923","DOI":"10.21873\/invivo.13520","volume":"38","author":"K Ito","year":"2024","unstructured":"Ito K, Koseki T, Morisaku M, Yamada S, Hayakawa N. Cytomegalovirus occurrence and time-to-onset analysis under bendamustine with anti-CD20 antibodies using the JADER database. In Vivo. 2024;38:923\u20137.","journal-title":"In Vivo"},{"key":"4084_CR35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/10428194.2022.2131426","volume":"64","author":"N Iriyama","year":"2023","unstructured":"Iriyama N, Miura K, Takahashi H, Nakagawa M, Iizuka K, Hamada T, et al. Clinical entity of cytomegalovirus disease in patients with malignant lymphoma on bendamustine therapy: a single-institution experience. Leuk Lymphoma. 2023;64:171\u20137.","journal-title":"Leuk Lymphoma"},{"key":"4084_CR36","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1007\/s00277-024-05839-0","volume":"103","author":"J-P Huang","year":"2024","unstructured":"Huang J-P, Yeh C-M, Gong Y-W, Tsai M-H, Lin Y-T, Tsai C-K, et al. Risk and impact of cytomegalovirus infection in lymphoma patients treated with bendamustine. Ann Hematol. 2024;103:4099\u2013109.","journal-title":"Ann Hematol"},{"key":"4084_CR37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386:351\u201363.","journal-title":"N Engl J Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04084-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04084-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04084-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T14:50:40Z","timestamp":1771339840000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04084-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4084"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04084-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"21 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}